NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing antiviral drugs called nanoviricides using nanomedicine technology. Their lead drug candidate, NV-387, completed Phase Ia/Ib clinical trials with no adverse events and is advancing to Phase II trials for Ebola and Mpox treatment in the DRC. The company targets viral diseases using host-mimetic nanomachines designed to bind, engulf, and destroy virus particles without relying on the patient's immune system.
expected 2026-12-29
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-09-28 | 2026-06-30 | 0001104659-26-111390 | EDGAR | 97K words |
| 2025-09-29 | 2025-06-30 | 0001104659-25-094527 | EDGAR | 87K words |
| 2024-09-27 | 2024-06-30 | 0001410578-24-001650 | EDGAR | 82K words |
| 2023-10-13 | 2023-06-30 | 0001410578-23-002146 | EDGAR | 75K words |
| 2022-10-13 | 2022-06-30 | 0001410578-22-002878 | EDGAR | 92K words |
| 2021-10-12 | 2021-06-30 | 0001104659-21-125343 | EDGAR | 97K words |
| 2020-10-13 | 2020-06-30 | 0001104659-20-114577 | EDGAR | 95K words |
| 2019-08-23 | 2019-06-30 | 0001144204-19-041547 | EDGAR | 79K words |
| 2018-10-12 | 2018-06-30 | 0001144204-18-053665 | EDGAR | 82K words |
| 2017-09-28 | 2017-06-30 | 0001144204-17-050412 | EDGAR | 84K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001104659-26-016476 | EDGAR | 35K words |
| 2025-11-14 | 2025-09-30 | 0001104659-25-112608 | EDGAR | 32K words |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001336 | EDGAR | 31K words |
| 2025-02-14 | 2024-12-31 | 0001410578-25-000140 | EDGAR | 29K words |
| 2024-11-14 | 2024-09-30 | 0001410578-24-001991 | EDGAR | 26K words |
| 2024-05-15 | 2024-03-31 | 0001410578-24-000843 | EDGAR | 28K words |
| 2024-02-14 | 2023-12-31 | 0001410578-24-000048 | EDGAR | 25K words |
| 2023-11-14 | 2023-09-30 | 0001410578-23-002484 | EDGAR | 22K words |
| 2023-05-15 | 2023-03-31 | 0001410578-23-001235 | EDGAR | 23K words |
| 2023-02-14 | 2022-12-31 | 0001410578-23-000129 | EDGAR | 19K words |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003398 | EDGAR | 27K words |
| 2022-05-16 | 2022-03-31 | 0001410578-22-001688 | EDGAR | 35K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-29 | 0001104659-26-111952 | EDGAR | 1K words |
| 2026-07-30 | 0001104659-26-088393 | EDGAR | 1K words |
| 2026-07-17 | 0001104659-26-084668 | EDGAR | 22K words |
| 2025-11-26 | 0001104659-25-116457 | EDGAR | 1K words |
| 2025-11-14 | 0001104659-25-112644 | EDGAR | 2K words |
| 2025-10-01 | 0001104659-25-095676 | EDGAR | 4K words |
| 2024-12-12 | 0001104659-24-128066 | EDGAR | 1K words |
| 2024-08-09 | 0001104659-24-087828 | EDGAR | 1K words |
| 2024-04-05 | 0001104659-24-044367 | EDGAR | 22K words |
| 2024-02-16 | 0001104659-24-024973 | EDGAR | 10K words |
253 total filings indexed. 221 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001379006 |
| Ticker | NNVC |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Shelton, Connecticut |
| Website | https://www.nanoviricides.com |
| Listed | 2005-07-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NNVC (~200 tokens, structured JSON with cryptographic provenance)